NCT06092216 - Spesolimab in Pyoderma Gangrenosum | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 23, 2023

Primary Completion Date

January 14, 2025

Study Completion Date

January 14, 2025

Conditions

Pyoderma Gangrenosum

Interventions

DRUG

Spesolimab

"900 mg of spesolimab intravenously (IV) administered every 4 weeks at Visits 2, 3, 4, 5, 6, 7, 8, 9.~If at visit 4 dosing schedule changes to every 3 weeks, Spesolimab will be administered at Visits 2, 3, 4, 5, 6, 8, 9, 10 and 11."

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York